Shufro Rose & Co’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.01M | Sell |
2,598
-37
| -1% | -$28.3K | 0.14% | 80 |
|
|
2025
Q4 | $2.03M | Buy |
2,635
+12
| +0.5% | +$8.15K | 0.14% | 77 |
|
|
2025
Q3 | $1.66M | Hold |
2,623
| – | – | 0.14% | 86 |
|
|
2025
Q2 | $1.66M | Sell |
2,623
-16
| -0.6% | -$8.93K | 0.13% | 86 |
|
|
2025
Q1 | $1.67M | Sell |
2,639
-47
| -2% | -$32.3K | 0.13% | 88 |
|
|
2024
Q4 | $1.91M | Buy |
2,686
+2,393
| +817% | +$2.01M | 0.15% | 80 |
|
|
2024
Q3 | $308K | Hold |
293
| – | – | 0.03% | 234 |
|
|
2024
Q2 | $308K | Hold |
293
| – | – | 0.03% | 234 |
|
|
2024
Q1 | $282K | Hold |
293
| – | – | 0.02% | 240 |
|
|
2023
Q4 | $241K | Hold |
293
| – | – | 0.02% | 245 |
|
|
2023
Q3 | $241K | Sell |
293
-50
| -15% | -$39.3K | 0.02% | 245 |
|
|
2023
Q2 | $246K | Sell |
343
-100
| -23% | -$77.1K | 0.02% | 247 |
|
|
2023
Q1 | $364K | Hold |
443
| – | – | 0.03% | 204 |
|
|
2022
Q4 | $320K | Hold |
443
| – | – | 0.03% | 224 |
|
|
2022
Q3 | $305K | Hold |
443
| – | – | 0.03% | 222 |
|
|
2022
Q2 | $262K | Sell |
443
-15
| -3% | -$9.75K | 0.02% | 240 |
|
|
2022
Q1 | $320K | Sell |
458
-388
| -46% | -$245K | 0.02% | 226 |
|
|
2021
Q4 | $534K | Buy |
846
+12
| +1% | +$7.38K | 0.04% | 178 |
|
|
2021
Q3 | $505K | Hold |
834
| – | – | 0.04% | 172 |
|
|
2021
Q2 | $466K | Buy |
834
+4
| +0.5% | +$2.03K | 0.04% | 168 |
|
|
2021
Q1 | $393K | Hold |
830
| – | – | 0.03% | 187 |
|
|
2020
Q4 | $401K | Buy |
830
+230
| +38% | +$124K | 0.03% | 177 |
|
|
2020
Q3 | $336K | Hold |
600
| – | – | 0.03% | 198 |
|
|
2020
Q2 | $374K | Hold |
600
| – | – | 0.04% | 184 |
|
|
2020
Q1 | $293K | Hold |
600
| – | – | 0.03% | 200 |
|
|
2019
Q4 | $225K | Buy |
+600
| New | +$202K | 0.02% | 264 |
|
|
2019
Q2 | – | Sell |
-600
| Closed | -$246K | – | 313 |
|
|
2019
Q1 | $246K | Hold |
600
| – | – | 0.02% | 239 |
|
|
2018
Q4 | $224K | Hold |
600
| – | – | 0.02% | 237 |
|
|
2018
Q3 | $242K | Hold |
600
| – | – | 0.02% | 254 |
|
|
2018
Q2 | $207K | Sell |
600
-100
| -14% | -$31.3K | 0.02% | 258 |
|
|
2018
Q1 | $241K | Hold |
700
| – | – | 0.02% | 250 |
|
|
2017
Q4 | $263K | Buy |
700
+100
| +17% | +$40.5K | 0.03% | 237 |
|
|
2017
Q3 | $268K | Buy |
+600
| New | +$286K | 0.03% | 240 |
|
|
2016
Q3 | – | Sell |
-600
| Closed | -$210K | – | 273 |
|
|
2016
Q2 | $210K | Sell |
600
-2,737
| -82% | -$1.05M | 0.02% | 234 |
|
|
2016
Q1 | $1.2M | Buy |
+3,337
| New | +$1.38M | 0.13% | 104 |
|
Other funds holding REGN
VCM
N
Shufro Rose & Co's REGN Position: Q1 2026 in Review
Shufro Rose & Co reduced its Regeneron Pharmaceuticals (REGN) stake by 1.4% in Q1 2026, selling an estimated $28.3K and leaving 2,598 shares worth $2.01M. The position accounts for 0.14% of the portfolio, ranked #80.
Shufro Rose & Co first reported a position in REGN in Q1 2016 and has held it in 35 quarters since. The position peaked at $2.03M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Shufro Rose & Co held 2,598 shares of Regeneron Pharmaceuticals worth $2.01M as of Q1 2026.
- Shufro Rose & Co sold 37 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $28.3K.
- Regeneron Pharmaceuticals made up 0.14% of Shufro Rose & Co's portfolio in Q1 2026, its #80 holding.
- Shufro Rose & Co first reported a position in Regeneron Pharmaceuticals in Q1 2016 and has held it in 35 quarters since.
- Shufro Rose & Co's Regeneron Pharmaceuticals position peaked at $2.03M in Q4 2025.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Shufro Rose & Co's 13F filing for Q1 2026, filed 15 May 2026.